Harry Penner

Mr. Harry H.
Penner, Jr., is an Executive Chairman at New Haven Pharmaceuticals, Inc., a Chairman & Chief Executive Officer at Nascent BioScience LLC, a Chairman at Celldex Therapeutics, Inc. and an Executive Chairman at Prevention Pharmaceuticals, Inc. He is on the Board of Directors at Aria Neurosciences, Inc., CaroGen Corp., MAKScientific LLC, Neurovail, Inc. and Omax Health, Inc. Mr. Penner was previously employed as a Chairman by QCDx LLC, a Lead Director by Altus Pharmaceuticals, Inc., a Chairman & Chief Executive Officer by Nascent BioSciences Inc., an Independent Director by Melinta Subsidiary Corp., a Vice Chairman, President & Chief Executive Officer by Neurogen Corp., a President & EVP-North America by Novo Nordisk North America, Inc., an Executive Vice President by Novo Nordisk A/S, a Chairman by Affinimark Technologies, Inc., a Chairman by Celldex Therapeutics, Inc. (Old), a Chairman by Connecticut Board of Governors for Higher Education, a Chairman by Connecticut Technology Council, a Co-Chairman by Connecticut United for Research Excellence, Inc., a Chairman by RHEI Pharmaceuticals, Inc., and a Chairman by Virscio, Inc. He also served on the board at Immedica Pharma US, Inc., AVANT Immunotherapeutics, Inc., Connecticut Business & Industry Association, Genaissance Pharmaceuticals, Inc. and Ikonisys, Inc. He received his undergraduate degree from the University of Virginia, a graduate degree from Fordham University and a graduate degree from New York University.